Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose Stem Cells for COPD
NCT02161744Phase 1Terminated
- Sponsor
- Arkansas Heart Hospital
- Start
- Oct 2013
- Primary completion
- Oct 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in chronic obstructive pulmonary disease (COPD), sponsored by Arkansas Heart Hospital. Primary endpoint: Safety of adipose derived stem cells at 12 months. Started Oct 2013; status: terminated.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02161744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161744.